Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"EnGeneIC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EnGeneIC Announces Acceptance of Abstract to the Annual Meeting of the American Society of Clinical Oncology 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for\u00a0COVID-19 Vaccine and Cancer Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EnGeneIC Publishes The COVID-EDV Vaccine\u2019s Novel Mechanism of Action in A Leading Immunology Journal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by EnGeneIC

    Menu

    EnGeneIC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              EnGeneIC

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EnGeneIC Publishes The COVID-EDV Vaccine’s Novel Mechanism of Action in A Leading Immunology Journal

              Details:

              This paper illustrates that the COVID-EDV vaccine is a fundamental change in thinking on how to produce an effective and inexpensive vaccine and has broad-reaching ramifications for vaccinology.

              Lead Product(s): COVID-EDV

              Therapeutic Area: Infections and Infectious Diseases Product Name: COVID-EDV

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EnGeneIC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment

              Details:

              Under the deal, EnGeneIC will grant ImmunityBio an exclusive, worldwide licence to develop, manufacture and commercialize EDV™ in combination with its anti-cancer drugs and COVID-19 vaccine.

              Lead Product(s): EnGeneIC Dream Vector,Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: EDV

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: ImmunityBio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EnGeneIC

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EnGeneIC Announces Acceptance of Abstract to the Annual Meeting of the American Society of Clinical Oncology 2020

              Details:

              Abstract demonstrates promising early results from PHASE I/IIA study in patients with recurrent, metastatic pancreatic cancer.

              Lead Product(s): E-EDV-D682,EDV-GC

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY